中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2014年
2期
121-124,后插2
,共5页
缪世梅%达展云%王爱萍%周燕%徐学康
繆世梅%達展雲%王愛萍%週燕%徐學康
무세매%체전운%왕애평%주연%서학강
狼疮肾炎%免疫抑制法%MRL/lpr狼疮小鼠%多靶点疗法
狼瘡腎炎%免疫抑製法%MRL/lpr狼瘡小鼠%多靶點療法
랑창신염%면역억제법%MRL/lpr랑창소서%다파점요법
Lupus nephritis%Immunosupression%MRL/lpr mice%Multi-target immune therapy
目的 探讨半量泼尼松、环磷酰胺与来氟米特联合多靶点免疫抑制治疗MRL/lpr小鼠LN的疗效及安全性,为临床寻找安全、有效、价廉的治疗LN方案提供实验依据.方法 10周龄雌性MRL/lpr狼疮小鼠28只,采用随机数字表法分成4组,每组7只,A组:空白对照组,B组:经典对照组,C组:全量联合对照组,D组:半量联合治疗组.治疗12周后进行疗效及安全性评价.采用单因素方差分析、q检验、Pearson相关分析进行统计学处理.结果 治疗12周后,B组、C组、D组与A组比较,抗dsDNA抗体滴度(0.43±0.16,0.32±0.09,0.44±0.18,1.95±0.19) U/ml、尿蛋白定量(24 h)水平降低(1.63 ±0.63,0.40±0.23,0.82±0.21,10.86±2.17) mg、血肌酐水平(71±8,60±5,68±3,121±10) μmol/L及生存率差异均有统计学意义(P<0.05),B组、C组、D组肾组织病理损害均较A组减轻.B组、C组、D组的疗效相当,不良反应D组最轻,C组最重.结论 泼尼松、环磷酰胺与来氟米特半量多靶点免疫抑制联合治疗MRL/lpr小鼠LN与经典组、全量组相比,疗效相当,不良反应减轻.本研究为临床探索价廉、安全、有效,便于推广的新的多靶点免疫抑制剂治疗方案提供了实验依据.
目的 探討半量潑尼鬆、環燐酰胺與來氟米特聯閤多靶點免疫抑製治療MRL/lpr小鼠LN的療效及安全性,為臨床尋找安全、有效、價廉的治療LN方案提供實驗依據.方法 10週齡雌性MRL/lpr狼瘡小鼠28隻,採用隨機數字錶法分成4組,每組7隻,A組:空白對照組,B組:經典對照組,C組:全量聯閤對照組,D組:半量聯閤治療組.治療12週後進行療效及安全性評價.採用單因素方差分析、q檢驗、Pearson相關分析進行統計學處理.結果 治療12週後,B組、C組、D組與A組比較,抗dsDNA抗體滴度(0.43±0.16,0.32±0.09,0.44±0.18,1.95±0.19) U/ml、尿蛋白定量(24 h)水平降低(1.63 ±0.63,0.40±0.23,0.82±0.21,10.86±2.17) mg、血肌酐水平(71±8,60±5,68±3,121±10) μmol/L及生存率差異均有統計學意義(P<0.05),B組、C組、D組腎組織病理損害均較A組減輕.B組、C組、D組的療效相噹,不良反應D組最輕,C組最重.結論 潑尼鬆、環燐酰胺與來氟米特半量多靶點免疫抑製聯閤治療MRL/lpr小鼠LN與經典組、全量組相比,療效相噹,不良反應減輕.本研究為臨床探索價廉、安全、有效,便于推廣的新的多靶點免疫抑製劑治療方案提供瞭實驗依據.
목적 탐토반량발니송、배린선알여래불미특연합다파점면역억제치료MRL/lpr소서LN적료효급안전성,위림상심조안전、유효、개렴적치료LN방안제공실험의거.방법 10주령자성MRL/lpr랑창소서28지,채용수궤수자표법분성4조,매조7지,A조:공백대조조,B조:경전대조조,C조:전량연합대조조,D조:반량연합치료조.치료12주후진행료효급안전성평개.채용단인소방차분석、q검험、Pearson상관분석진행통계학처리.결과 치료12주후,B조、C조、D조여A조비교,항dsDNA항체적도(0.43±0.16,0.32±0.09,0.44±0.18,1.95±0.19) U/ml、뇨단백정량(24 h)수평강저(1.63 ±0.63,0.40±0.23,0.82±0.21,10.86±2.17) mg、혈기항수평(71±8,60±5,68±3,121±10) μmol/L급생존솔차이균유통계학의의(P<0.05),B조、C조、D조신조직병리손해균교A조감경.B조、C조、D조적료효상당,불량반응D조최경,C조최중.결론 발니송、배린선알여래불미특반량다파점면역억제연합치료MRL/lpr소서LN여경전조、전량조상비,료효상당,불량반응감경.본연구위림상탐색개렴、안전、유효,편우추엄적신적다파점면역억제제치료방안제공료실험의거.
Objective To investigate the efficacy and adverse reactions of half-dose glucocorticosteroid and cytoxan,combined with leflunomide for the treatment of lupus nephritis (LN) of MRL/lpr mice,and provide experimental evidences for LN therapy.Methods Twenty-eight 10-week-old MRL/lpr mice were randomly divided into four groups:Group A,blank control group; Group B,classical control group; Group C,full-dose control group; Group D,half-dose treatment group,with 7 mice in each group.The therapeutic efficacy and side reactions in the four groups were observed and compared before and 12 weeks after treatment.Statistical analysis was conducted with one-way ANOVA,q test and Pearson's correlation analysis.Results The serum anti-double stranded DNA (anti-dsDNA) antibody titers (0.43±0.16,0.32±0.09,0.44± 0.18,1.95±0.19) U/ml,serum creatinine level (1.63±0.63,0.40±0.23,0.82±0.21,10.86±2.17) mg,24-hour urine protein excretion level (71±8,60±5,68±3,121±10) μmol/L and renal pathological changes in group B,C,D were significantly improved than those of the group A (P<0.05) after 12 weeks treatment.There was no significant difference in the efficacy between group B,C,and D (P>0.05).The incidence of adverse reactions in group D was significantly lower than that in other groups (P<0.05).Conclusion Multi-target therapy,such as half-dose prednisone and CTX,combined with leflunomide can effectively control lupus disease activity with less side effects.This regimen is cheap,safe and effective for the treatment of LN in MRUL/lpr mice.This study has provided animal evidences for this multi-target therapy for LN.